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Abstract
Thiamin diphosphate (ThDP)-dependent enzymes constitute a large class of enzymes that catalyze a diverse range of reactions.
Many are involved in stereospecific carbon–carbon bond formation and, consequently, have found increasing interest and utility as
chiral catalysts in various biocatalytic applications. All ThDP-catalyzed reactions require the reaction of the ThDP ylide (the acti-
vated state of the cofactor) with the substrate. Given that the cofactor can adopt up to seven states on an enzyme, identifying the
factors affecting the stability of the pre-reactant states is important for the overall understanding of the kinetics and mechanism of
the individual reactions.
In this paper we use density functional theory calculations to systematically study the different cofactor states in terms of energies
and geometries. Benzoylformate decarboxylase (BFDC), which is a well characterized chiral catalyst, serves as the prototypical
ThDP-dependent enzyme. A model of the active site was constructed on the basis of available crystal structures, and the cofactor
states were characterized in the presence of three different ligands (crystallographic water, benzoylformate as substrate, and
(R)-mandelate as inhibitor). Overall, the calculations reveal that the relative stabilities of the cofactor states are greatly affected by
the presence and identity of the bound ligands. A surprising finding is that benzoylformate binding, while favoring ylide formation,
provided even greater stabilization to a catalytically inactive tricyclic state. Conversely, the inhibitor binding greatly destabilized
the ylide formation. Together, these observations have significant implications for the reaction kinetics of the ThDP-dependent en-
zymes, and, potentially, for the use of unnatural substrates in such reactions.
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Scheme 1: The variety of forms of enzyme-bound ThDP.
Introduction
Enzymes that depend on thiamin diphosphate (ThDP,
Scheme 1) can be found in a wide range of metabolic pathways.
Although they are known to catalyze the formation of C–N,
C–O and C–S bonds, ThDP-dependent enzymes generally cata-
lyze the breakdown and formation of C–C bonds adjacent to a
carbonyl group [1,2]. The resultant 2-hydroxyketones are often
chiral, so these enzymes are being increasingly studied for their
use as biocatalysts in the preparation of pharmaceuticals and
agrochemicals [3]. ThDP is an unusual cofactor in that, even
without the enzyme, it can catalyze many of these reactions [2].
For example, the decarboxylation of pyruvate in water can be
accomplished by ThDP, but when it is bound to the enzyme
pyruvate decarboxylase (PDC), the decarboxylation rate is in-
creased by 12 orders of magnitude [2,4]. Clearly, the catalytic
power of the cofactor is greatly enhanced by the enzyme-bound
environment. A fundamental understanding of how this en-
hancement is achieved could potentially lead to the develop-
ment of new and improved biocatalysts.
At a minimum, ThDP-catalyzed reactions all require the forma-
tion of a C2-carbanion or ylide [5] (Scheme 1). This is achieved
through a series of proton transfers during which several differ-
ent states of the cofactor are formed [6]. Starting from the
neutral form of ThDP (AP), the cofactor can be protonated at
the N1′ position, resulting in the APH+ state. With only one
known exception [7], the protonation/deprotonation of the
N1′ position is performed by a highly conserved glutamic acid
residue that is thought to stabilize the imino tautomer IP [6].
The subsequent loss of a proton from N4′ of APH+ gives the
IP state. Deprotonation of the C2 position results in the ylide
form which can be either protonated (YIH+) or deprotonated
(YI) at the N1′ position. The C2 deprotonation is believed to be
performed by the N4′ nitrogen [2,8,9], and is assisted by the
cofactor being held in a “V” conformation in which the imino
group is located within a hydrogen bonding distance of the C2
of the thiazolium ring [9-14].
While the importance of the catalytically critical ylide was
readily recognized, obtaining evidence for the participation of
the 4′-amino group and the imino tautomer IP proved more
challenging. Initially, model compounds were used to identify
the signature UV absorbances for the IP form of ThDP. These
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were then used to demonstrate the presence of IP on yeast PDC
[15]. Subsequently, the IP form was shown to have a positive
CD signal around 300–310 nm, while a negative peak around
320–330 nm, similar to that observed upon binding of ThDP to
apo transketolase [16], was assigned to the AP form [15].
These, along with signature CD and UV signals for intermedi-
ates further along the reaction pathway, have now been ob-
served for more than 10 ThDP-dependent enzymes [6,17]. As
yet, no electronic signature has been observed for the APH+
form. However, solid-state NMR using 15N and 13C-labeled
ThDP has been used to identify APH+ on pyruvate decarboxy-
lase and the E1 component of the pyruvate dehydrogenase com-
plex [18].
In addition to the plethora of experimental investigations, a
number of computational studies have addressed issues
regarding the various states of ThDP. For example, in some
very early work, Jordan used semi-empirical methods to study
the electronic structure and conformational space of the cofactor
in the gas phase, acknowledging the difficulty of comparing
these results to reactions in solution and on the enzyme [19,20].
Thirty years later, density functional theory (DFT) calculations
showed that the 4′-amino moiety of the cofactor can either
accept or donate a proton in the reactions, depending on the pro-
tonation state of N1′ [21].
Orbital analysis of the IP/YIH+ reaction showed that full for-
mation of ylide was dependent on deprotonation of N1′ and,
consistent with experimental findings, deprotonation was, in
turn, likely dependent on conformational changes induced by
the presence of substrate [22]. More recently, the relative stabil-
ities of a number of the ThDP states (AP, APH+, IP and YI)
were obtained using DFT methods, employing a model of the
cofactor along with the hydrogen-bonding carboxylate moiety
[23]. Subsequently, a similar approach was used to characterize
the nucleophilicity of the N1′ and N4′ centers [24]. In many
cases, rather than simply focus on the cofactor, computational
studies have been used to investigate full reaction mechanisms
of ThDP enzymes, including pyruvate decarboxylase (PDC)
[25-28], benzoylformate decarboxylase (BFDC) [29,30], aceto-
hydroxy acid synthase [24,31-35], pyruvate dehydrogenase
(PDH) [36], benzaldehyde lyase [37], cyclohexane dione hydro-
lase [38], oxalyl-CoA decarboxylase [39], DXP synthase [40]
and transketolase [41,42].
It is surprising that almost none of these studies acknowledged
that there is a second, albeit less well discussed, path for the
ThDP cofactor, i.e., the formation of a tricyclic, dihydrothia-
chromine species from the AP form [43-45]. Nucleophilic
attack of N4′ on C2 results in the formation of a C2–N4′ bond,
giving rise to the tricyclic intermediate TCH+. Loss of the N1′
proton TCH+ will result in the TC form of the cofactor [45].
While admittedly not common, the tricyclic form of the cofactor
has been observed on at least two ThDP-dependent enzymes.
Dihydrothiachromine diphosphate (TC) was observed in the
X-ray structure of phosphoketolase from Bifidobacterium breve
[46], and its hydroxyethyl derivative was identified in the struc-
ture of acetolactate synthase from Klebsiella pneumoniae whose
crystals had been soaked with pyruvate [47].
In a very recent study, we used quantum chemical methodolo-
gy to investigate the detailed reaction mechanism of benzoylfor-
mate decarboxylase (BFDC) [29]. A model of the active site
was designed on the basis of the X-ray structure of BFDC in
complex with the substrate analog inhibitor, (R)-mandelate. In
that study all intermediates and transition states were located
and characterized. Intriguingly, we identified the tricyclic
TCH+ state of the cofactor as an off-cycle intermediate species.
It was found to be about 5 kcal/mol lower in energy than the
IP state, thereby raising the barrier for the formation of the
cofactor–substrate adduct (C2α-mandelyl–ThDP). Of course
this has important implications for the overall kinetics of any
BFDC-catalyzed reaction and, potentially, for all THDP-de-
pendent enzymes [29].
This unexpected result prompted us to conduct a systematic
study of the energetics of the various enzyme-bound states of
ThDP (Scheme 1). To this end, we have used BFDC as a repre-
sentative ThDP-dependent enzyme, and employed the quantum
chemical approach used to study the BFDC reaction mecha-
nism to characterize the various states of the ThDP cofactor.
Models representing different enzymatic and non-enzymatic
environments have been generated and, for each model, the
cofactor has been characterized in terms of energies and geome-
tries.
Results
The various states of the cofactor have been studied using five
different models. In all cases the diphosphate group is omitted
since it is thought to act primarily as an anchor for the cofactor
and, consequently, was not deemed relevant to the current
study. Model A is the simplest, representing the cofactor alone
in solution. It comprises 31 atoms and has a net charge of +1.
Models B–E represent the cofactor in the BFDC active site in
the absence and presence of bound ligands. The active site
model is built on the basis of the crystal structure (PDB ID
1MCZ) and is identical to that used in the mechanistic study
[29]. As shown in Figure 1, the model comprises all groups that
make up the active site pocket, including residues that surround
the ThDP cofactor and the ligand. A detailed description of the
residues included in the model and the choice of protonation
states is provided in reference [29].
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Figure 1: A) 2D representation of ThDP (blue) and the residues included in the active site models, and B) optimized structure of model B with an
empty active site. Asterisks mark atoms that were kept fixed to their crystallographic positions during the geometry optimization. The BFDC active site
has contributions from two monomers and primes re-used to indicate residues from the second monomer. For clarity, the non-polar hydrogens of the
residues are not included.
In model B the active site does not contain any ligand, and is
considered for comparative purposes. It has a total of 291 atoms
and a net charge of 0. In model C the active site contains a crys-
tallographic water molecule and includes 294 atoms with net
charge of 0. In model D the water is replaced by the benzoylfor-
mate substrate in its deprotonated form and has thus 307 atoms
Beilstein J. Org. Chem. 2019, 15, 145–159.
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Figure 2: Optimized structures of the states of ThDP in the absence of enzyme (model A). Relative energies are indicated in kcal/mol.
and a net charge of −1. Finally, in model E the active site
contains (R)-mandelate, again in its deprotonated form, and
consists of 309 atoms with a net charge of −1. In the active site
models B–E a number of atoms are kept fixed in the geometry
optimizations in order to preserve the overall structure of the
active site and avoid excessive movements of the various
groups. The fixed atoms are indicated by asterisks in Figure 1B.
The states of the ThDP cofactor considered here are shown in
Scheme 1. The starting point for each model is the AP state, the
energy of which is set to zero, and the energies of the other
states are then compared to it.
Model A: cofactor in solution
In order to analyze the effect of the enzyme environment on the
properties of the various ThDP states, it is important to first
consider the solution states of the cofactor in the absence of en-
zyme. The calculations show that the difference in energy be-
tween the lowest energy conformer and the typical V-conforma-
tion of enzyme-bound ThDP [48] is 4.2 kcal/mol. Interestingly,
the lowest energy structure also adopts a V-shape, but one in
which thiazolium ring is perpendicular to the pyrimidine ring
(see Supporting Information File 1 for an optimized structure).
Given that this study compares enzyme-bound states of ThDP,
it is appropriate to use the typical V-conformation of the AP
form as the starting/reference point. With that in mind, the opti-
mized geometries of the various V-states of the cofactor alone
are displayed in Figure 2.
Calculations on model A show that the AP state is the most
stable, but the tricyclic form TCH+ is only 2.8 kcal/mol higher
in energy (Table 1). Presumably the proximity of N4' to C2 in
the V-conformation makes this state more accessible than it
would be if ThDP was unconstrained in solution. Both the IP
and YIH+ states are considerably higher in energy, at +6.4 and
+15.2 kcal/mol, respectively. It should be noted that the acid/
base conjugates of these states (APH+, TC and YI, respective-
ly) were not calculated, as these structures would have different
Beilstein J. Org. Chem. 2019, 15, 145–159.
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Figure 3: Optimized structures of the states of BFDC-bound ThDP in the absence of ligand (model B). Relative energies are indicated in kcal/mol. For
clarity, only a selected part of the model is shown, for full model, see Figure 1.
numbers of atoms and so the energies would not be directly
comparable.
Table 1: Calculated relative energies (kcal/mol) of the various ThDP
states. The most stable state for each model is indicated in bold face.
state model A model B model C model D model E
AP 0.0 0.0 0.0 0.0 0.0
APH+ – +1.2a +1.9a +3.0 −0.3
IP +6.4 +12.8 +16.0 −0.9 +10.2
YI – +11.6 +11.0 +3.0 +23.2
YIH+ +15.2 +11.3a +11.1a +6.0 +20.2
TC – +2.6 +8.9 −4.9 +7.9
TCH+ +2.8 +2.0a +8.5a −6.3 +11.3
aValues are calculated with the N1′–H distance constrained to 1.15 Å
(see text).
Model B: ThDP in the empty active site
Model B represents ThDP in the active site of BFDC in the
absence of ligand. The geometries of the different ThDP states
were optimized (Figure 3) and their energies evaluated
(Table 1). Here, the enzyme provides both electrostatic and
steric interactions with ThDP, all of which are expected to
affect the cofactor’s geometry and energy. Of particular interest
is the conserved Glu47 residue which forms a hydrogen bond to
N1' of the pyrimidine ring. It is important to note that, during
the geometry optimizations of the three states YIH+, APH+
and TCH+, the N1' proton invariably transferred spontaneously
to the carboxylate of Glu47 thereby yielding the conjugated
states YI, AP and TC. In order to assess independently the
effect of the N1′ protonation state, approximate energies of
YIH+, APH+ and TCH+ were calculated by restraining the
N1′–H distance to 1.15 Å. Even with that constraint the ener-
gies obtained are within 2 kcal/mol of those of their conjugates
(Table 1), showing that N1′ protonation/deprotonation has
Beilstein J. Org. Chem. 2019, 15, 145–159.
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Figure 4: Optimized structures of the ThDP states for the model including the crystallographic water (model C). Relative energies are indicated in
kcal/mol.
only marginal impact on the relative energies of the cofactor
states.
In the AP state, His70 interacts with the cofactor through a
hydrogen bond between the Nε and the exocyclic N4' amino
group, a bond that is not present in the other states. With that
notable exception, the overall geometries of the different states
are quite similar, and bond distances are also fairly consistent
(Figure 3).
As with model A, the AP state is found to be the lowest energy
state in model B. The stability of TC state in model B is similar
to that of the TCH+ in the model of the cofactor alone (+2.6
compared to +2.8 kcal/mol, respectively).The energy of the YI
state is also reasonably close to that of YIH+ in the cofactor
alone (+11.6 vs +15.2 kcal/mol, relative to their respective
AP states). Indeed, it was not until the energy of the IP state
was calculated that the enzyme showed any significant effect. In
this instance the IP state was calculated to be 12.8 kcal/mol
higher than AP, i.e., more than 6 kcal/mol higher than the value
calculated in the absence of enzyme.
Model C: active site including the
crystallographic water
In the X-ray structure of unliganded BFDC, there is a crystallo-
graphic water molecule that is displaced when a ligand is
present [13,49]. In model C, that water molecule is included
and is found to bind in the same position regardless of the state
of the cofactor. A superposition with the crystal structure with-
out substrate (PDB 1BFD) shows that the model calculations
reproduce very well the position of this water (see Supporting
Information File 1), even though the hydrogen-bonding pattern
of the water molecule changes somewhat between the states
(Figure 4). Interestingly, there is a hydrogen bond from the
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water to the anionic C2 carbon in the YI state (OH…C distance
of 1.91 Å), with the negative charge on C2 further stabilized by
interaction with the exocyclic NH2 group (NH…C distance of
2.17 Å). The superposition of the structures of model B and
model C reveals that inclusion of the water molecule causes
also a slight movement of the thiazolium ring of the cofactor
towards the interior of the active site cavity (see Supporting
Information File 1).
Energetically, we note that the IP state is destabilized com-
pared to that in model B, now being 16.0 kcal/mol higher than
AP, an increase of 3.2 kcal/mol. Conversely, the stability of the
YI state was very similar (+11.0 vs +11.6 kcal/mol) to that ob-
served for model B suggesting the water molecule has little
effect on the stability of the ylide. However, the water mole-
cule reserves its largest effect for the TC state which now is
8.9 kcal/mol less stable than AP, an increase of 6.3 kcal/mol
over that observed in model B. Overall, it would appear that the
effect of the water molecule is to stabilize the AP state com-
pared to the other states. The exception is the YI state, which
seemingly benefits from the new hydrogen bond from the water
molecule to the C2 carbanion.
Finally, as with model B, the geometries for the YIH+, APH+
and TCH+ states could not be obtained, as geometry optimiza-
tions lead to their respective conjugates. However, constrained
optimizations again show that the energies are not affected sig-
nificantly by the protonation (see Table 1).
Model D: active site including benzoylformate
In model D, which includes the native substrate, benzoylfor-
mate (BF), all the states shown in Scheme 1 could be located by
the geometry optimizations. As with the crystallographic water
in model C, the presence of the substrate pushes the thiazolium
ring somewhat towards the interior of the cavity. In all ThDP
states the carboxylate of BF forms hydrogen bonds to the side
chain hydroxy group and the backbone NH of Ser26, and to the
Nε of His281 (Figure 5). In the AP and APH+ states, the Nδ of
His70 accepts a hydrogen bond from the exocyclic NH2 group,
with an N…HN distance of 2.1 Å. In the other states, the Nε of
His70 is protonated and donates a hydrogen bond to the carbon-
yl of the substrate. In YI and YIH+, the exocyclic NH2 inter-
acts with the C2 carbanion of the thiazolium ring.
Strikingly, the presence of the substrate has a dramatic impact
on the relative stabilities of the various states as compared to
the water (model C) or the empty cavity (model B). Presum-
ably this effect is primarily due to the overall negative charge of
the benzoylformate and the bulk of the phenyl substituent. The
most significant changes are seen in the energies of the two cat-
alytically productive states, IP and YI. Now, the former is more
stable, by 0.9 kcal/mol, than the AP state. This may not seem
much but the overall change is substantial as the IP state was
calculated to be 6.4, 12.8 and 16.0 kcal/mol higher in energy
than the AP state in models A, B, and C, respectively. The
energy of the ylide is also lowered in the presence of the sub-
strate and the YI state is now only +3.0 kcal/mol compared
to AP. In the other models the difference was more than
11 kcal/mol (Table 1).
Although these results clearly suggest that substrate binding
results in catalytically productive states of the cofactor, this is
not the whole story. Model D also indicates that substrate
binding produces a major stabilization of the two non-produc-
tive tricyclic species. In fact, the most stable state is found to be
TCH+, which is calculated to be 6.3 kcal/mol more stable than
the AP state. Also the deprotonated TC state is 4.9 kcal/mol
more stable than AP, and both tricyclic states are at least
4 kcal/mol lower in energy than the IP form. While substrate
binding favoring the non-productive species is surprising and
seems counterintuitive, benzoylformate binding also makes the
catalytically essential IP and YI forms more accessible than in
any of the other models. Importantly, as detailed in our recent
paper on the reaction mechanism of BFDC, this model is
consistent with the kinetics of the BFDC reaction [29].
In a final note on model D, although the calculations show that
proton transfer from N1' to Glu47 is not spontaneous in this
model, the energy difference between the conjugated pairs
AP/APH+, TC/TCH+, YI/YIH+ remains very low, suggesting
the forms are readily interchangeable (Table 1).
Model E: active site of BFDC with
(R)-mandelate bound
In model E, in which the active site of BFDC contains the in-
hibitor (R)-mandelate, the hydrogen-bonding network is very
similar to that of benzoylformate in model D. However, as
shown in Figure 6, the benzylic hydroxy group provides a
source of additional interactions. In the AP and APH+ states,
the hydroxy group forms hydrogen bonds with His70 and the
exocyclic NH2. Support was lent to the validity of model E
when superposition of the structure of the APH+ form on the
structure of BFDC:(R)-mandelate complex (PDB 1MCZ)
showed no major movements (see Supporting Information
File 1). In the other states, the bond to His 70 is maintained
but that to the exocyclic NH2 is broken. Instead the hydroxy
group forms a hydrogen bond to the backbone carbonyl of
Gly401.
Energetically, we note that, in this model, AP/APH+ are by far
the most stable states with the IP, YI and TC states being 10.2,
23.2 and 7.9 kcal/mol higher than AP, respectively (Table 1).
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Figure 5: Optimized structures of the ThDP states in the BFDC active site containing the substrate, benzoylformate (model D). Relative energies are
indicated in kcal/mol.
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Figure 6: Optimized structures of the ThDP states for the model including (R)-mandelate (model E). Relative energies are indicated in kcal/mol.
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Further, each of these states is more than 10 kcal/mol higher in
energy relative to the AP state than its counterpart in model D
in which the substrate is bound (Table 1). Clearly the binding of
the (R)-mandelate causes a stabilization of the AP/APH+ states
relative to the others.
As seen from Table 1, despite having the same overall charge
and similar bulkiness of the substituents, the binding of the
benzoylformate (model D) and (R)-mandelate (model E) result
in quite different energies. The superposition of the AP states of
the two models (see Supporting Information File 1) shows that
the additional hydrogen bond provided by the benzylic hydroxy
group of (R)-mandelate (vide supra) contributes significantly to
this difference. Further, changing from the sp2 carbonyl carbon
to the sp3 benzylic carbon results in a substantial movement of
the substituent oxygen which also contributes to the energy
difference between the models.
According to Table 1 the AP/APH+ forms are the most stable
states for models C and E, i.e., BFDC in the absence of ligand
and in the presence of (R)-mandelate. The CD spectrum of
BFDC shows a small minimum at around 325 nm, attributed to
the AP form. Titrating BFDC with methyl benzoylphosphonate
(MBP), a mechanism-based inhibitor, gave rise to a new
maximum at around 300 nm, attributed to the IP form, with a
concurrent loss of signal at 325 nm [50]. Based on the data in
Table 1, it is not certain that the titration with benzoylformate
would give rise to the IP form. However, the data unambigu-
ously suggest that titration of BFDC with (R)-mandelate should
result in no change in its CD spectrum, even when the enzyme
is saturated. Accordingly, the titration was carried out and,
indeed, even at (R)-mandelate concentrations well in excess of
its Ki value of 1 mM [49], no change in the spectrum was ob-
served (see Supporting Information File 1 for details).
Discussion
Since it was first purified from beer yeast over 80 years ago
[51], the structure of ThDP and its related intermediates and
ionization states have undergone intensive investigation (sum-
marized in references [2,52]). Most of these investigations have
focused on the structure and properties of the covalently modi-
fied ThDP intermediates of diverse ThDP-dependent enzymes.
Less attention has been paid to the variety of states the cofactor
itself can adopt on the enzyme. As shown in Scheme 1, when
various tautomers and ionization states are included, ThDP can
adopt at least seven forms on any given ThDP-dependent en-
zyme. This is prior to any reaction taking place. Most of these
are accounted for in typical analyses [52] but the two tricyclic
forms, TC and TCH+, are rarely considered. Unlike the
tricyclic states, which could be regarded to be non-productive,
the IP and the YI forms arising from it are essential for cataly-
sis and always considered in any mechanistic study. However,
conceivably all seven states could be energetically accessible
and could influence the catalytic mechanism. Over the past
several years there has been an increasing use of ThDP-depend-
ent enzymes as chiral catalysts [53]. Given that all of these en-
zymes will require ready access to the IP and YI forms, it
seemed logical to take a closer look at the relative energies of
the various states and how those energies may be affected by
the binding of different ligands. Toward that end, we have used
DFT calculations to explore the energetics of the various states
of enzyme-bound ThDP using benzoylformate decarboxylase as
the model enzyme.
The work was predicated on two elements. First, that the
cofactor was held in a V-conformation on the enzyme, and
second, that the resting (reference) state of the cofactor was the
AP form. Both have been confirmed experimentally [13,49,50]
and are typical of most, if not all, of the ThDP-dependent en-
zymes studied to date. In total, five models were employed:
models A and B providing a comparison of the cofactor states
in the presence and absence of enzyme, and models C–E exam-
ining the effects of active site ligands.
Models A and B both predict the AP state to be the most stable,
vindicating its use as the reference state. Perhaps the first
surprise was the difference in magnitude and overall effect the
active site ligands had on the relative energy levels. For exam-
ple, the simple addition of a crystallographic water destabilized
both the IP and TC forms by 3 and 6 kcal/mol, respectively,
thereby ensuring that BFDC largely exists as the AP form. Even
more surprising was the comparison of the substrate, benzoyl-
formate, and the inhibitor, (R)-mandelate. With the exception of
an sp3 rather than sp2 hybridized benzylic carbon, (R)-mande-
late is identical to benzoylformate. However, they have
markedly different effects on the states of the cofactor. In model
C, corresponding to the native enzyme, the IP form is
16 kcal/mol less stable than the AP form. When benzoylfor-
mate binds (model D), the IP form becomes energetically
favored by 0.9 kcal/mol, an overall change of 17 kcal/mol. This
is accompanied by an 8 kcal/mol stabilization of the catalytical-
ly essential YI form. Conversely, when the inhibitor is bound
(model E), the IP and YI forms are ca. 10 and 20 kcal/mol less
stable than in model D. Clearly the substrate-induced changes
combine to facilitate catalysis, while those brought about by the
inhibitor make reaction more difficult.
Considering that they have been largely ignored in previous
studies, the next surprise was that the tricyclic forms TC and
TCH+ were relatively stable, in both the absence and presence
of enzyme. In fact, it seemed that the primary effect of the
binding of ThDP to the enzyme was to bring about the destabi-
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lization of the IP form. Over all five models, the tricyclic forms
were consistently more energetically stable than the catalytical-
ly essential IP and YI forms (Table 1). While it may be argued
that stabilization of the tricyclic forms could prove to be en-
zyme specific, the relatively low energy of the tricyclic state in
the absence of enzyme cannot be disregarded, and certainly sug-
gests that the TC/TCH+ forms may be more common than pre-
viously recognized. Further, and consistent with results for the
YI/YIH+ forms, the relative stabilities of TC/TCH+ states
proved to be ligand specific. In model C, the AP form is ca.
9 kcal/mol more stable than the TC/TCH+ forms. However,
after substrate binding (model D) the TC/TCH+ states are ca.
5 kcal/mol more stable than AP. Thus, the presence of benzoyl-
formate shifts the relative energies by 14 kcal/mol and, concom-
itantly, makes the tricyclic forms the most stable species. The
inhibitor again provides the contrast, for the binding of
(R)-mandelate (model E) has virtually no effect on the relative
energy levels of the tricyclic forms, and AP remains clearly the
most stable state.
At this point, it is reasonable to assess the validity of the cur-
rent computational results in light of available experimental
information. In the first instance the results confirm that the
AP state is the lowest energy, i.e., resting state. This was one of
the elements on which the work was predicated and is consis-
tent with data obtained from, among others, BFDC, benzalde-
hyde lyase, pyruvate oxidase, pyruvate decarboxylase and the
E1 subunit of the pyruvate dehydrogenase complex (summa-
rized in [54]). In fact, there are only two cases in which the
IP form has been observed in the resting enzyme, namely pyru-
vate oxidase and the pyruvate dehydrogenase complex. In both
cases, the AP state was the predominant form [54].
Secondly, the results show that substrate binding dramatically
lowers the energy of the IP and YI states, which would,
presumably, increase the rate and extent of ylide formation.
This observation is more difficult to demonstrate experimental-
ly. While H/D exchange experiments have been used as a
measure of the rate of ylide formation, substrate activation has
only been observed with allosteric enzymes such as yeast PDC
[8]. Further, even though there is a CD signature for the
IP state, it is usually associated with formation of a tetrahedral
reaction intermediate. As a result it is difficult to separate any
increase in the IP signal arising from substrate binding from
that due to intermediate formation. Possibly the closest to ex-
perimental support came from an experiment in which the reac-
tion of BFDC with MBP was monitored by stopped-flow mea-
surements at 308 nm using the intrinsic absorbance of the
IP state. In that case the results implied that there was a tran-
sient formation of a Michaelis complex which was accompa-
nied by an increase in the IP form [55].
Next, the calculations suggest that the binding of (R)-mandelate
should not change the state of the cofactor. Again, somewhat
difficult to prove conclusively but titration of BFDC with the
substrate analogue, MBP, provided clear evidence for the
conversion of the AP to the IP state for the former. Conversely,
and consistent with predictions, the AP state remained un-
changed when a similar titration was carried out with the inhibi-
tor, (R)-mandelate (see Supporting Information File 1).
Finally, what evidence is there for the formation of tricyclic
states? As noted in the introduction, there has been little or no
effort to identify tricyclic intermediates on ThDP-dependent en-
zymes. Critically, even though they were treated dismissively,
there are two X-ray structures which, at a minimum, provide
unambiguous evidence for the formation of stable tricyclic
intermediates on an enzyme [46,47]. Additional evidence, albeit
more indirect, comes from an inhibition study using omepra-
zole, which was predicted to possibly interact with ThDP-de-
pendent enzymes. The prediction was based on the similarity of
omeprazole to the tricyclic form of thiamin. This was con-
firmed experimentally when omeprazole was subsequently
shown to be a competitive inhibitor of both transketolase and
PDC, with a Ki value for the latter only ca. 20 times the Km for
ThDP measured in the same experiment [56].
The current calculations show that, in the presence of substrate,
TC/TCH+ are the most stable states of ThDP on BFDC. Yet,
even though a large number of high-resolution structures of
BFDC variants, in the presence and absence of ligands, have
been determined, none of them shows the tricyclic intermediate.
This may seem surprising but it must be considered that when
benzoylformate is present the catalytic cycle is in operation,
reactions are running and covalent ThDP intermediates are
being formed. As detailed in our recent paper, the enamine is
the most stable reaction intermediate [29], which makes it
unlikely that the TC state will be detected experimentally.
Furthermore, in the absence of the substrate (model C) or in the
presence of the inhibitor (model E), the TC states are clearly
disfavored, with calculated energies of +8.9 and +7.9 kcal/mol,
respectively, relative to the AP state.
Are the tricyclic forms even relevant? That is really the crux of
the matter, and the answer is, for BFDC at least, yes! It is im-
portant to note that the tricyclic forms TC/TCH+ are calculated
to be more stable than the ylide forms YI/YIH+ in all consid-
ered models. Further, the calculations on model D indicate that
an energy penalty of ca. 5 kcal/mol must be paid to go from
the TCH+ to the YI state, which is the catalytically active
form of the cofactor. This, in turn, effectively increases the
barrier for formation of the first reaction intermediate. In fact,
as shown in the paper on the catalytic mechanism that inspired
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this work, the energy barrier brought about by the stable
tricyclic state fits well with the experimental evidence for
the slow first step, i.e., formation of the mandelylThDP adduct
[29].
In addition to BFDC, the X-ray structures of tricyclic intermedi-
ates suggest that an even greater stabilization is present on
phosphoketolase and acetolactate synthase. It could well be
argued that TC stabilization may prove to be rare and specific
to only a few enzymes. Yet, the relatively low energy of the
tricyclic state in the absence of enzyme cannot be disregarded,
and certainly suggests that the TC forms may be more common
than previously thought. Over the past few years, a rapid-
quench NMR technique has been employed to determine micro-
scopic rate constants for elementary steps in several ThDP-de-
pendent enzymes. It is notable that, in addition to BFDC [55],
E. coli AHAS I and II [57], glyoxylate carboligase [7], DXP
synthase [58] and indolepyruvate decarboxylase [59] all have
formation of the first tetrahedral intermediate as the rate-deter-
mining step. Of course, in the absence of the corresponding
calculations it is impossible to definitively state that this is due
to stabilization of the TC state, but the question is worth asking.
The pyruvate oxidase from Lactobacillus plantarum provides
some support in that both the AP and IP forms are present in
the resting enzyme [54] and decarboxylation, rather than forma-
tion of the first intermediate, was found to be rate limiting [60].
On the other hand, product release was the slowest step for
ZmPDC and ScPDC [61], so clearly not all ThDP-dependent en-
zymes behave in the same manner.
Of course, while the relative stability of the TC form may slow
down the BFDC reaction, it is conceivable that it may also play
a beneficial role. As the pKa of the C2 proton decreases, the ac-
tivity of the ThDP cofactor increases [62]. However, concomi-
tantly, the thiazolium ring becomes more susceptible to hydro-
lysis to a catalytically inactive form [44]. The stable tricyclic
form of the cofactor, which can readily revert to its active form,
may provide a protective mechanism against hydrolysis [44].
Two final thoughts: first, the current results show that even
when substrate is bound, the tricyclic state, not the ylide, is the
most energetically stable. This observation implies that starting
the computational investigations of the ThDP-dependent cata-
lytic mechanism directly from the ylide, as done in numerous
examples in the literature, may give rise to an incomplete, if not
inaccurate, picture of the energy profile of the reaction. Second,
many ThDP-dependent enzymes are being evaluated for use as
biocatalysts. The stark difference in the effect of two very simi-
lar ligands, benzoylformate and (R)-mandelate, on the activa-
tion of the cofactor suggests that the use of alternative sub-
strates or, possibly more importantly, the evolution of ThDP-de-
pendent enzymes to accept a wide range of non-native sub-
strates, might not be as simple as may have been expected.
Experimental
All calculations were performed with the B3LYP-D3(BJ)
[62-65] density functional method and using the Gaussian 09
package [66]. The geometries were optimized with the
6-31G(d,p) basis set, and the energy of the stationary points was
refined by single-point calculations with 6-311+G(2d,2p) basis
set. Frequency calculations were done at the same level of
theory as the optimizations to obtain zero-point energy correc-
tions, and solvation energies were calculated using the implicit
solvent method SMD [67] with a dielectric constant ε = 4.
Supporting Information
Supporting Information File 1
Lowest-energy conformation of model A, superpositions of
the AP state/model C and APH+ state/model E with crystal
structures, superposition of the AP state/models B and C,
superposition of the AP states/models D and E,
experimental CD spectra, calculated energies and energy
corrections, and Cartesian coordinates of all optimized
structures.
[https://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-15-15-S1.pdf]
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